Pathogenesis and treatment progress of coagulation dysfunction after traumatic brain injury

doi:10.3877/cma.j.issn.2095-9141.2016.03.013

Abstract

Abstract:

There is a close relationship between the traumatic brain injury and the functional changes of coagulation system. However, there is still a lack of in-depth study on the mechanism of the interaction between the two. The high coagulation state and low coagulation state after traumatic brain injury can lead to the formation of micro thrombosis or aggravate intracranial hemorrhage, which can lead to a series of secondary injury. Therefore, researchers have proposed several hypotheses, such as tissue factor release, disseminated intravascular coagulation, fibrinolysis and platelet dysfunction etc. This article reviews the pathogenesis, clinical diagnosis, treatment and prognosis of the abnormal coagulation function after traumatic brain injury.

Key words: Traumatic brain injury, Arauma-induced coagulopathy, Tissue factor

Quan Zhang, Hengli Tian. Pathogenesis and treatment progress of coagulation dysfunction after traumatic brain injury[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2016, 02(03): 173-177.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2016.03.013

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2016/V02/I03/173

Figures/Tables 1

References 52

[1]	Epstein DS,Mitra B,O’Reilly G, et al. Acute traumatic coagulopathy in the setting of isolated traumatic brain injury: a systematic review and meta-analysis[J]. Injury, 2014, 45(5): 819-824.
[2]	Mccully SP,Schreiber MA. Traumatic brain injury and its effect on coagulopathy[J]. Semin Thromb Hemost, 2013, 39(8): 896-901.
[3]	Maegele M,Schochl H,Cohen MJ. An update on the coagulopathy of trauma[J]. Shock, 2014, 41: 21-25.
[4]	Venugopal A. Disseminated intravascular coagulation[J]. Indian J Anaesth, 2014, 58(5): 603-608.
[5]	Figueroa SA,Merriman-Noesges K. Utility of thromboelastography in traumatic brain injury and the neuroscience intensive care unit[J]. J Neurosci Nurs, 2014, 46(2): 66-70.
[6]	Massaro AM,Doerfler S,Nawalinski K, et al. Thromboelastography defines late hypercoagulability after TBI: a pilot study[J]. Neurocrit Care, 2015, 22(1): 45-51.
[7]	Chapman MP,Moore EE,Ramos CR, et al. Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy[J]. J Trauma Acute Care Surg, 2013, 75(6): 961-967.
[8]	Chu AJ. Tissue factor, blood coagulation, and beyond: an overview[J]. Int J Inflam, 2011, 2011: 367284.
[9]	Kurland D,Hong C,Aarabi B, et al. Hemorrhagic progression of a contusion after traumatic brain injury: a review[J]. J Neurotrauma, 2012, 29(1): 19-31.
[10]	Palta S,Saroa R,Palta A. Overview of the coagulation system[J]. Indian J Anaesth, 2014, 58(5): 515-523.
[11]	Halpern CH,Reilly PM,Turtz AR, et al. Traumatic coagulopathy: the effect of brain injury[J]. J Neurotrauma, 2008, 25(8): 997-1001.
[12]	Lustenberger T,Talving P,Kobayashi L, et al. Time course of coagulopathy in isolated severe traumatic brain injury[J]. Injury, 2010, 41(9): 924-928.
[13]	Genet GF,Johansson PI,Meyer MA, et al. Trauma-induced coagulopathy: standard coagulation tests, biomarkers of coagulopathy, and endothelial damage in patients with traumatic brain injury[J]. J Neurotrauma, 2013, 30(4): 301-306.
[14]	Lee TH,Hampton DA,Diggs BS, et al. Traumatic brain injury is not associated with coagulopathy out of proportion to injury in other body regions[J]. J Trauma Acute Care Surg, 2014, 77(1): 67-72.
[15]	Heemskerk JW,Bevers EM,Lindhout T. Platelet activation and blood coagulation[J]. Thromb Haemost, 2002, 88(2): 186-193.
[16]	Wohlauer MV,Moore EE,Thomas S, et al. Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma[J]. J Am Coll Surg, 2012, 214(5): 739-746.
[17]	Kutcher ME,Redick BJ,Mccreery RC, et al. Characterization of platelet dysfunction after trauma[J]. J Trauma Acute Care Surg, 2012, 73(1): 13-19.
[18]	Davis PK,Musunuru H,Walsh M, et al. Platelet dysfunction is an early marker for traumatic brain injury-induced coagulopathy[J]. Neurocrit Care, 2012, 18(2): 201-208.
[19]	Castellino FJ,Chapman MP,Donahue DL, et al. Traumatic brain injury causes platelet adenosine diphosphate and arachidonic acid receptor inhibition independent of hemorrhagic shock in humans and rats[J]. J Trauma Acute Care Surg, 2014, 76(5): 1169-1176.
[20]	Donahue DL,Beck J,Fritz B, et al. Early platelet dysfunction in a rodent model of blunt traumatic brain injury reflects the acute traumatic coagulopathy found in humans[J]. J Neurotrauma, 2014, 31(4): 404-410.
[21]	Ploplis VA,Donahue DL,Sandoval-Cooper MJ, et al. Systemic platelet dysfunction is the result of local dysregulated coagulation and platelet activation in the brain in a rat model of isolated traumatic brain injury[J]. J Neurotrauma, 2014, 31(19): 1672-1675.
[22]	Maegele M. Coagulopathy after traumatic brain injury: incidence, pathogenesis, and treatment options[J]. Transfusion, 2013, 53: 28S-37S.
[23]	Davenport R. Pathogenesis of acute traumatic coagulopathy[J].Transfusion, 2013, 53: 23S-27S.
[24]	Cohen MJ,Brohi K,Ganter MT, et al. Early coagulopathy after traumatic brain injury: the role of hypoperfusion and the protein C pathway[J]. J Trauma, 2007, 63(6): 1254-1261.
[25]	Lustenberger T,Talving P,Kobayashi L, et al. Early coagulopathy after isolated severe traumatic brain injury: relationship with hypoperfusion challenged[J]. J Trauma, 2010, 69(6): 1410-1414.
[26]	Tian Y,Salsbery B,Wang M, et al. Brain-derived microparticles induce systemic coagulation in a murine model of traumatic brain injury[J]. Blood, 2015, 125(13): 2151-2159.
[27]	Alexiou GA,Lianos G,Fotakopoulos G, et al. Admission glucose and coagulopathy occurrence in patients with traumatic brain injury[J]. Brain Inj, 2014, 28(4): 438-441.
[28]	Tanaka KA,Mazzeffi M,Durila M. Role of prothrombin complex concentrate in perioperative coagulation therapy[J]. J Intensive Care, 2014, 2(1): 60.
[29]	Joseph B,Amini A,Friese RS, et al. Factor IX complex for the correction of traumatic coagulopathy[J]. J Trauma Acute Care Surg, 2012, 72(4): 828-833.
[30]	Sarode R,Milling TJ Jr,Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study[J]. Circulation, 2013, 128(11): 1234-1243.
[31]	Joseph B,Hadjizacharia P,Aziz H, et al. Prothrombin complex concentrate: an effective therapy in reversing the coagulopathy of traumatic brain injury[J]. J Trauma Acute Care Surg, 2013, 74(1): 248-253.
[32]	Joseph B,Aziz H,Pandit V, et al. Prothrombin complex concentrate use in coagulopathy of lethal brain injuries increases organ donation[J]. Am Surg, 2014, 80(4): 335-338.
[33]	Huynh TK,Costello JL,Rebuck JA. Optimizing the dose of three-factor prothrombin complex concentrate in traumatic brain injury patients on warfarin therapy[J]. Pharmacotherapy, 2014, 34(3): 260-264.
[34]	Yuan Q,Wu X,Du ZY, et al. Low-dose recombinant factor VIIa for reversing coagulopathy in patients with isolated traumatic brain injury[J]. J Crit Care, 2015, 30(1): 116-120.
[35]	Brown CV,Foulkrod KH,Lopez D, et al. Recombinant factor VIIa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients[J]. J Trauma, 2010, 68(2): 348-352.
[36]	Kim B,Haque A,Arnaud FG, et al. Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury[J]. J Emerg Trauma Shock, 2014, 7(2): 102-111.
[37]	裴兵兵,栗超跃,路鑫,等.应用小剂量重组人凝血因子Ⅶa治疗单纯性颅脑创伤性凝血功能障碍[J].中华医学杂志, 2013, 93(23): 1780-1783.
[38]	Deloughery EP,Lenfesty B,Deloughery TG. The use of recombinant factor VIIa in warfarin patients with traumatic brain injury: a retrospective case-control study[J]. Blood Coagul Fibrinolysis, 2013, 24(3): 317-320.
[39]	Narayan RK,Maas AI,Marshall LF, et al. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial[J]. Neurosurgery, 2008, 62(4): 776-788.
[40]	McQuay N Jr,Cipolla J,Franges EZ, et al. The use of recombinant activated factor VIIa in coagulopathic traumatic brain injuries requiring emergent craniotomy: is it beneficial[J]? J Neurosurg, 2009, 111(4): 666-671.
[41]	Shakur H,Roberts I,Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial[J]. Lancet, 2010, 376(9734).
[42]	Roberts I,Shakur H,Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial[J]. Lancet, 2011, 377(9771): 1096-1101.
[43]	Collaborators C. Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study)[J]. BMJ, 2011, 343(7): 369-369.
[44]	Perel P,Al-Shahi Salman R,Kawahara T, et al. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial[J]. Health Technol Assess, 2012, 16(13): 1-54.
[45]	Morrison JJ,Dubose JJ,Rasmussen TE, et al. Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) sStudy[J]. Arch Surg, 2012, 147(2): 113-119.
[46]	Spahn DR,Bouillon B,Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline[J]. Crit Care, 2013, 17(2): R76.
[47]	Bachelani AM,Bautz JT,Sperry JL, et al. Assessment of platelet transfusion for reversal of aspirin after traumatic brain injury[J]. Surgery, 2011, 150(4): 836-843.
[48]	Brasel KJ,Vercruysse G,Spinella PC, et al. The association of blood component use ratios with the survival of massively transfused trauma patients with and without severe brain injury[J]. J Trauma, 2011, 71(2 Suppl 3): S343-352.
[49]	Anglin CO,Spence JS,Warner MA, et al. Effects of platelet and plasma transfusion on outcome in traumatic brain injury patients with moderate bleeding diatheses[J]. J Neurosurg, 2013, 118(3): 676-686.
[50]	Briggs A,Gates JD,Kaufman RM, et al. Platelet dysfunction and platelet transfusion in traumatic brain injury[J]. J Surg Res, 2015, 193(2): 802-806.
[51]	Etemadrezaie H,Baharvahdat H,Shariati Z, et al. The effect of fresh frozen plasma in severe closed head injury[J]. Clin Neurol Neurosurg, 2007, 109(2): 166-171.
[52]	Peiniger S,Nienaber U,Lefering R, et al. Balanced massive transfusion ratios in multiple injury patients with traumatic brain injury[J]. Crit Care, 2011, 15(1): R68.

作者（年份）	ATC的定义	ATC发生率
Cohen(2007)	PT和PTT异常	28.0%
Talving(2009)	PLT<100 000或INR>1.1或aPTT>36 s	34.0%
Lustenberger(2010)	PLT<100 000或INR>1.1或aPTT>36 s	36.4%
Wafaisade(2010)	PLT<100 000或INR<1.1	22.7%
Schochl(2011)	PTI>70%或aPTT>35 s或纤维蛋白原<150 mg/DL或PLT<100 000	15.8%
Genet(2013)	aPTT>35 s或INR>1.2	13.0%

作者（年份）	ATC的定义	ATC发生率
Cohen(2007)	PT和PTT异常	28.0%
Talving(2009)	PLT<100 000或INR>1.1或aPTT>36 s	34.0%
Lustenberger(2010)	PLT<100 000或INR>1.1或aPTT>36 s	36.4%
Wafaisade(2010)	PLT<100 000或INR<1.1	22.7%
Schochl(2011)	PTI>70%或aPTT>35 s或纤维蛋白原<150 mg/DL或PLT<100 000	15.8%
Genet(2013)	aPTT>35 s或INR>1.2	13.0%

Please choose a citation manager

Content to export